The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Efficacy and safety of oral basal insulin versus subcutaneous insulin glargine in type 2 diabetes: a randomised, double-blind, phase 2 trial
Abstract
BACKGROUND Oral insulin 338 (I338) is a long-acting, basal insulin analogue formulated in a tablet with the absorption-enhancer sodium caprate. We investigated the efficacy and safety of I338 versus subcutaneous insulin glargine (IGlar) in patients with type 2 diabetes. METHODS This was a phase 2, 8-week, randomised, double-blind, double-dummy, active-controlled, parallel trial completed at two research institutes in Germany. Insulin-naive adult patients with type 2 diabetes, inadequately controlled on metformin monotherapy or combined with other oral antidiabetic drugs (HbA1c 7·0-10·0%; BMI 25·0-40·0 kg/m2), were randomly assigned (1:1) to receive once-daily I338 plus subcutaneous placebo (I338 group) or once-daily IGlar plus oral placebo (IGlar group). Randomisation occurred by interactive web response system stratified by baseline treatment with oral antidiabetic drugs. Patients and investigators were masked to treatment assignment. Weekly insulin dose titration aimed to achieve a self-measured fasting plasma glucose (FPG) concentration of 4·4-7·0 mmol/L. The recommended daily starting doses were 2700 nmol I338 or 10 U IGlar, and maximum allowed doses throughout the trial were 16 200 nmol I338 or 60 U IGlar. The primary endpoint was treatment difference in FPG concentration at 8 weeks for all randomly assigned patients receiving at least one dose of trial product (ie, the full analysis set). The trial has been completed and is registered at ClinicalTrials.gov, number NCT02470039. FINDINGS Between June 1, 2015, and Oct 19, 2015, 82 patients were screened for eligibility and 50 patients were randomly assigned to the I338 group (n=25) or the IGlar group (n=25). Mean FPG concentration at baseline was 9·7 (SD 2·8) in the I338 group and 9·1 (1·7) in the IGlar group. Least square mean FPG concentration at 8 weeks was 7·1 mmol/L (95% CI 6·4-7·8) in the I338 group and 6·8 mmol/L (6·5-7·1) in the IGlar group, with no significant treatment difference (0·3 mmol/L [-0·5 to 1·1]; p=0·46). I338 and IGlar were well tolerated by patients. Adverse events were reported in 15 (60%) patients in the I338 group and 17 (68%) patients in the IGlar group. The most common adverse events were diarrhoea (three [12%] patients in each group) and nasopharyngitis (five [20%] in the I338 group and two [8%] in the IGlar group). Most adverse events were graded mild (47 of 68 events), and no severe adverse events were reported. One patient in the IGlar group had a treatment-emergent serious adverse event (urogenital haemorrhage of moderate intensity, assessed by the investigator as unlikely to be related to treatment; the patient recovered). Incidence of hypoglycaemia was low in both groups (n=7 events in the I338 group; n=11 in the IGlar group), with no severe episodes. INTERPRETATION I338 can safely improve glycaemic control in insulin-naive patients with type 2 diabetes with no evidence of a difference compared with insulin glargine, a widely used subcutaneously administered basal insulin. Further development of this particular oral insulin project was discontinued because I338 doses were high and, therefore, production of the required quantities of I338 for wide public use was deemed not commercially viable. Improvement of technologies involved in the product's development is the focus of ongoing research. FUNDING Novo Nordisk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Seaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · Diabetes Care · doi:10.2337/dc12-2480 · Cited by 1,389
Insulin Degludec Versus Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes
Zinman, B., Philis-Tsimikas, A., Cariou, B., Handelsman, Y., Rodbard, H. W., Johansen, T., Endahl, L., Mathieu, C., & on behalf of the NN1250-3579 (BEGIN Once Long) Trial Investigators (2012) · Diabetes Care · doi:10.2337/dc12-1205 · Cited by 336
Insulin action on the liver in vivo
Cherrington, A. D., Moore, M. C., Sindelar, D. K., & Edgerton, D. S. (2007) · Biochemical Society Transactions · doi:10.1042/bst0351171 · Cited by 43
Cited by
Advances in oral peptide therapeutics
Drucker, D. J. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0053-0 · Cited by 646
Materials for oral delivery of proteins and peptides
Brown, T. D., Whitehead, K. A., & Mitragotri, S. (2019) · Nature Reviews Materials · doi:10.1038/s41578-019-0156-6 · Cited by 520
Systemic delivery of peptides by the oral route: Formulation and medicinal chemistry approaches
Brayden, D. J., Hill, T. A., Fairlie, D. P., Maher, S., & Mrsny, R. J. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.05.007 · Cited by 253
Insulin Therapy in Adults with Type 1 Diabetes Mellitus: a Narrative Review
Janež, A., Guja, C., Mitrakou, A., Lalic, N., Tankova, T., Czupryniak, L., Tabák, A. G., Prazny, M., Martinka, E., & Smircic-Duvnjak, L. (2020) · Diabetes Therapy · doi:10.1007/s13300-019-00743-7 · Cited by 177
Aroda, V. R., Blonde, L., & Pratley, R. E. (2022) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-022-09735-8 · Cited by 135
Metadata
- Authors
- Halberg, I. B., Lyby, K., Wassermann, K., Heise, T., Zijlstra, E., & Plum-Mörschel, L.
- Venue
- The Lancet Diabetes & Endocrinology
- Publisher
- Elsevier BV
- Published
- 2019-03
- Volume
- 7
- Issue
- 3
- Pages
- 179-188
- ISSN
- 2213-8587 (ISSN-L)
- OpenAlex
- W2911680209
- Cited by
- 178
- References
- 3
- FWCI
- 16.52
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and safety of oral basal insulin versus subcutaneous insulin glargine in type 2 diabetes: a randomised, double-blind, phase 2 trial. https://app.cochat.ai/papers/10.1016/s2213-8587(18)30372-3
- The paper
- Halberg, I. B., Lyby, K., Wassermann, K., Heise, T., Zijlstra, E., & Plum-Mörschel, L. (2019). Efficacy and safety of oral basal insulin versus subcutaneous insulin glargine in type 2 diabetes: a randomised, double-blind, phase 2 trial. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(18)30372-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.